|Solubility||Soluble in DMSO or ethanol.|
|Declaration||Manufactured by SynKinase.|
|Other Product Data||
Target: PDGFR | Kinase Group: RTK | Substrate: Tyrosine
Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. Axitinib is marketed under the name Inlyta®, and if one previous systemic therapy for kidney cell cancer has failed, axitinib is indicated. The IC(50) numbers reported for Axitinib are sub to low nanomolar in range.
- Sunitinib: from rational design to clinical efficacy: L.Q. Chow & S.G. Eckhardt; J. Clin. Oncol. 25, 884 (2007)
- Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors: K. Lee, et al.; Eur. J. Med. Chem. 45, 5420 (2010)
- The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents: R. Laufer, et al.; J. Med. Chem. 56, 6069 (2013)